SEC Company Response from VOLITIONRX LTD (VNRX) (CIK 0000093314) (VNRX) — Dec 21, 2011
VOLITIONRX LTD (VNRX) (CIK 0000093314)
Date: Dec. 21, 2011 · CIK: 0000093314 · Accession: 0001078782-11-003721
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-30402
Letter
Securities and Exchange Commission Division of Corporation Finance Filed October 13, 2011 File No. 000-30402 Form 8-K/A Filed November 1, 2011
Re:
Dear Mr. Williamson:
VolitionRX Limited, a Delaware corporation (the “Company”), has received and reviewed your letter of November 23, 2011 (the “Comment Letter”), pertaining to the Company’s Form 8-K (the “Filing”) filed October 13, 2011 and the Company’s Form 8-K/A filed November 1, 2011 with the Securities & Exchange Commission (the “Commission”).
On December 6, 2011, the Company requested an extension from the Commission to submit a written reply to the Comment Letter by December 23, 2011. However, the Company is still in the process of preparing and reviewing the financial statements of Singapore Volition for the quarter ended September 30, 2011, pursuant to Comment No. 2 in the Comment Letter. Per my discussion today with Brian McAllister, we hope to submit our written reply to the Commission within 10 business days of today’s date, no later than January 6, 2012. Again, we apologize for the delay in responding to the comment letter.
In connection with the comments in your letter, we acknowledge that:
·
The Company is responsible for the adequacy and accuracy of the disclosure in the filing;
·
Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
·
The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Again, we apologize for our delay. Please do not hesitate to contact us if you have any questions or comments in regard to this letter or the information contained herein.
Very truly yours,
VolitionRX Limited
Show Raw Text
CORRESP 1 filename1.htm SEC Correspondence December 21, 2011 Jay Williamson Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, DC 20549 Re: VolitionRX Limited Form 8-K Filed October 13, 2011 File No. 000-30402 Form 8-K/A Filed November 1, 2011 Dear Mr. Williamson: VolitionRX Limited, a Delaware corporation (the “Company”), has received and reviewed your letter of November 23, 2011 (the “Comment Letter”), pertaining to the Company’s Form 8-K (the “Filing”) filed October 13, 2011 and the Company’s Form 8-K/A filed November 1, 2011 with the Securities & Exchange Commission (the “Commission”). On December 6, 2011, the Company requested an extension from the Commission to submit a written reply to the Comment Letter by December 23, 2011. However, the Company is still in the process of preparing and reviewing the financial statements of Singapore Volition for the quarter ended September 30, 2011, pursuant to Comment No. 2 in the Comment Letter. Per my discussion today with Brian McAllister, we hope to submit our written reply to the Commission within 10 business days of today’s date, no later than January 6, 2012. Again, we apologize for the delay in responding to the comment letter. In connection with the comments in your letter, we acknowledge that: · The Company is responsible for the adequacy and accuracy of the disclosure in the filing; · Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and · The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Again, we apologize for our delay. Please do not hesitate to contact us if you have any questions or comments in regard to this letter or the information contained herein. Very truly yours, VolitionRX Limited /s/ Cameron Reynolds Cameron Reynolds President and Chief Executive Officer 150 Orchard Road Orchard Plaza 08-02 Singapore 238841